(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone
(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone Basic information
- Product Name:
- (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone
- Synonyms:
-
- (R)-N-[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-acetamide
- OR-1896
- (R)-N-(4-(4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide
- Acetamide, N-[4-[(4R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]-
- (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-p
- 13C,2H3]-Levosimendan metabolite
- OR 1896,OR1896
- (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone
- CAS:
- 220246-81-1
- MF:
- C13H15N3O2
- MW:
- 245.28
- Product Categories:
-
- Intermediates & Fine Chemicals
- Metabolites & Impurities
- Pharmaceuticals
- Aromatics
- Heterocycles
- Mol File:
- 220246-81-1.mol
(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone Chemical Properties
- Melting point:
- 224-226°C
- Density
- 1.27±0.1 g/cm3(Predicted)
- storage temp.
- -20°C Freezer
- solubility
- Acetone (Slightly), DMSO (Slightly), Methanol (Slightly)
- form
- Solid
- pka
- 13.67±0.60(Predicted)
- color
- Pale Yellow to Light Yellow
- CAS DataBase Reference
- 220246-81-1
(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone Usage And Synthesis
Chemical Properties
Pale Yellow Solid
Uses
A metabolite of Levosimendan (L378000).
Definition
ChEBI: OR-1896 is an anilide and a member of acetamides.
in vivo
During the metabolism of Levosimendan approximately 5% of the drug is converted to the metabolite OR-1855 in the large intestine, and then acetylated in the liver to form the active metabolite OR-1896. Binding to plasma proteins is 98% for Levosimendan but only 40% for OR-1896. Unlike Levosimendan, which has an elimination half-life of 1-1.5 h, the half-life of OR-1896 is about 75 to 80 h allowing cardiovascular effects to persist up to 7 to 9 days after discontinuation of a 24-hour infusion of levosimendan. The pharmacokinetic of the parent drug is unaltered in subjects with severe renal impairment or with moderate hepatic impairment, whereas the elimination of its metabolites (OR-1896) can be prolonged[1].
IC 50
PDE3/PDE Ⅲ; K+ Channel; Drug Metabolite
(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinoneSupplier
- Tel
- 18210857532
- jkinfo@jkchemical.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 0755-83725681-603
- Tel
- 010-60605840 18892239720
- psaitong@jm-bio.com
(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone(220246-81-1)Related Product Information
- (R)-6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone
- Levosimendan Impurity 14
- Levosimendan
- 6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone
- LevosiMendan iMpurity
- Levosimendan Impurity 4
- 2-[2-[4-(2-Azidotetrahydro-3-Methyl-5-oxo-2-furanyl)phenyl]hydrazinylidene]propanedinitrile (Mixture of DiasteroMers)
- 5-Methyl-3(2H)-pyridazinone
- (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone